Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $855.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by Morgan Stanley from $779.00 to $855.00 in a research report report published on Monday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other research firms have also weighed in on REGN. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a “buy” rating in a report on Monday. Citigroup raised their price objective on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a research note on Friday, October 30th. Finally, Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $930.67 on Monday. Regeneron Pharmaceuticals has a 12 month low of $591.52 and a 12 month high of $991.73. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The stock has a market cap of $95.82 billion, a PE ratio of 20.38, a price-to-earnings-growth ratio of 1.45 and a beta of 0.10. The business has a fifty day simple moving average of $800.69 and a 200-day simple moving average of $741.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the prior year, the firm earned $11.83 EPS. The company’s revenue was up 36.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 51.64 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.30%.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares of the company’s stock, valued at $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the business’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 20,789 shares of company stock worth $18,766,698. Insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Lido Advisors LLC grew its position in Regeneron Pharmaceuticals by 26.0% during the 3rd quarter. Lido Advisors LLC now owns 14,677 shares of the biopharmaceutical company’s stock worth $11,129,000 after acquiring an additional 3,030 shares during the last quarter. Cornerstone Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $254,000. Csenge Advisory Group bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $237,000. Kestra Investment Management LLC raised its position in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 16 shares during the last quarter. Finally, AlphaCore Capital LLC boosted its stake in Regeneron Pharmaceuticals by 133.5% in the third quarter. AlphaCore Capital LLC now owns 1,602 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 916 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.